ANTICOAGULACIÓN ORAL

EN PACIENTES CON
ENFERMEDAD HEPÁTICA
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative
Review Stefano Ballestri . Mariano Capitelli . Giorgio Cioni Received: February 24, 2020 / Published online: April 13, 2020
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative
Review Stefano Ballestri . Mariano Capitelli . Giorgio Cioni Received: February 24, 2020 / Published online: April 13, 2020
 •∗ Los ACOD en dosis regulares son 20 mg de
rivaroxabán una vez al día, 150 mg de dabigatrán dos
veces al día, 5 mg de apixabán dos veces al día y 60 mg
de edoxabán una vez al día.

•↵ † Los ACOD en dosis reducidas son 15/10 mg de

rivaroxabán una vez al día, 110 mg de dabigatrán una vez
al día, 2,5 mg de apixaban dos veces al día y 30 mg de
edoxabán una vez al día.

Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative
Review Stefano Ballestri . Mariano Capitelli . Giorgio Cioni Received: February 24, 2020 / Published online: April 13, 2020
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative
Review Stefano Ballestri . Mariano Capitelli . Giorgio Cioni Received: February 24, 2020 / Published online: April 13, 2020
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative
Review Stefano Ballestri . Mariano Capitelli . Giorgio Cioni Received: February 24, 2020 / Published online: April 13, 2020